rs61754278
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PM1PM2PM5PP3_ModeratePP5_Very_Strong
The ENST00000369887.4(CYP17A1):c.1040G>A(p.Arg347His) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000125 in 1,603,438 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R347C) has been classified as Pathogenic.
Frequency
Consequence
ENST00000369887.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 16 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CYP17A1 | NM_000102.4 | c.1040G>A | p.Arg347His | missense_variant | 6/8 | ENST00000369887.4 | NP_000093.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CYP17A1 | ENST00000369887.4 | c.1040G>A | p.Arg347His | missense_variant | 6/8 | 1 | NM_000102.4 | ENSP00000358903 | P3 |
Frequencies
GnomAD3 genomes AF: 0.0000131 AC: 2AN: 152230Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000159 AC: 4AN: 251412Hom.: 0 AF XY: 0.0000221 AC XY: 3AN XY: 135878
GnomAD4 exome AF: 0.0000124 AC: 18AN: 1451208Hom.: 0 Cov.: 28 AF XY: 0.0000125 AC XY: 9AN XY: 722870
GnomAD4 genome AF: 0.0000131 AC: 2AN: 152230Hom.: 0 Cov.: 32 AF XY: 0.0000269 AC XY: 2AN XY: 74374
ClinVar
Submissions by phenotype
Deficiency of steroid 17-alpha-monooxygenase Pathogenic:5
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Oct 29, 2021 | Variant summary: CYP17A1 c.1040G>A (p.Arg347His) results in a non-conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 1.6e-05 in 251412 control chromosomes (gnomAD). c.1040G>A has been reported in the literature in multiple homozygous individuals affected with Isolated 17,20 Lyase Deficiency (Geller_1997, van den Akker_2002). These data indicate that the variant is very likely to be associated with disease. Experimental evidence evaluating an impact on protein function demonstrated the variant confers minimal 17,20-lyase activity while it retains 17-alpha-hydroxylase function (e.g. Geller_1997, Geller_1999, van den Akker_2002, Peng_2016, Kim_2021). Two ClinVar submitters (evaluation after 2014) cite the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Pathogenic, no assertion criteria provided | research | Division of Human Genetics, Children's Hospital of Philadelphia | Jun 10, 2015 | The CYP17A1 variant (c.1040G>A; p.Arg347His) was identified in four patients (mostly homozygotes and one compound heterozygote) with ambiguous external genitalia and normal glucocorticoid levels. Multiple functional studies showed moderate to severe impaired lyase activity, with some residual activity preserving the 17-alpha hydroxylase function. This variant is considered a pathogenic variant. - |
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Nov 17, 2021 | - - |
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Mar 02, 2020 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Dec 02, 2023 | - - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 10, 2023 | This sequence change replaces arginine, which is basic and polar, with histidine, which is basic and polar, at codon 347 of the CYP17A1 protein (p.Arg347His). This variant is present in population databases (rs61754278, gnomAD 0.007%). This missense change has been observed in individuals with isolated 17,20-lyase deficiency (PMID: 9326943, 12466376). ClinVar contains an entry for this variant (Variation ID: 1787). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt CYP17A1 protein function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects CYP17A1 function (PMID: 9326943, 9601054, 12466376, 27426448). This variant disrupts the p.Arg347 amino acid residue in CYP17A1. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 12466376). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. - |
17,20-lyase deficiency, isolated Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Dec 01, 2002 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at